Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Canceropen access

Authors
Park, Song EeChoi, Jin HwaChoi, Chang HwanPark, Suk WonKim, Beon GyuCha, Seong JaeHwang, In Gyu
Issue Date
2019
Publisher
IVYSPRING INT PUBL
Keywords
rectal cancer; preoperative therapy; chemotherapy; 5-fluorouracil (5-FU); leucovorin (LV)
Citation
JOURNAL OF CANCER, v.10, no.1, pp 186 - 191
Pages
6
Journal Title
JOURNAL OF CANCER
Volume
10
Number
1
Start Page
186
End Page
191
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/18611
DOI
10.7150/jca.25366
ISSN
1837-9664
Abstract
Purpose: The aim of the preliminary study was to evaluate the efficacy and safety of 4-week chemotherapy with 5-Fluorouracil and leucovorin (LV5FU2) during the resting periods between preoperative CRT and surgery in patients with LARC. Materials and Methods: Standard preoperative CRT was delivered to the entire pelvis at a total dose of 5040 Gy of radiation with concurrent 5-FU or capecitabine for 6 weeks. Twenty-three patients received additional preoperative chemotherapy with two cycles of 5-FU and LV (LV 200 mg/m2 and 5-FU bolus 400 mg/m2 on day 1, and 5-FU infusion 2400 mg/m2 for 46 hrs, every 2 weeks) after preoperative CRT. Surgery was performed at 2-4 weeks following the completion of preoperative chemotherapy. Results: Between May 2013 and January 2015, 23 patients underwent preoperative CRT, with additional chemotherapy and surgery, and 23 patients completed the scheduled treatment. The median follow-up duration was 42.0 months. The tumor down-staging rate was observed in 65.2%, and pathologic complete remission (pCR) was noted in 5 patients (21.7%). T and N down-staging were observed in 16 (69.6%) and 14 (60.9%) patients, respectively. The four-year disease-free survival (DFS) rate was 73.9% and the four-year overall survival (OS) rate was 90.9% in patients who received additional chemotherapy. The four-year DFS rate was 100% in the tumor down-staging group vs. 25.0% in the non-down staging group treated with additional chemotherapy (P < 0.001). There was also a significant difference of the four-year OS rate 100% in the tumor down-staging group compared with 71.4% in the non-down staging group (P = 0.031). Conclusions: This preliminary study showed that additional preoperative chemotherapy with LV5FU2 was well tolerable and had an improvement in the downstaging rate and survival. Randomized controlled trial of this strategy is encouraged for definitive conclusions.
Files in This Item
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Beom Gyu photo

Kim, Beom Gyu
의과대학 (의학부(임상-서울))
Read more

Altmetrics

Total Views & Downloads

BROWSE